Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation.

Kim M,Seung-Ah Yahng,Kwon A,Park J,Jeon Yw,Yoon Jh,Shin Sh,Lee Se,Cho Bs,Eom Ks,Lee S,Min Ck,Kim Hj,Seok-Goo Cho,Kim Dw,Lee Jw,Min Ws,Lee Sh,Kim Yj

Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation.

2015

Kim M
Seung-Ah Yahng
Kwon A
Park J
Jeon Yw
Yoon Jh
Shin Sh
Lee Se
Cho Bs
Eom Ks
Lee S
Min Ck
Kim Hj
Seok-Goo Cho
Kim Dw
Lee Jw
Min Ws
Lee Sh
Kim Yj

Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation

Keywords:

Progenitor cell
Immunology
Medicine
Diabetes mellitus
Graft-versus-host disease
Transplantation
Stem cell
Mutation
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations